AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova

[cafead]

via As antibody-drug conjugates make a steady comeback, AstraZeneca strikes its second deal this year with a Chinese company. The Cambridge-based biopharma announced Friday it’s putting potentially $600 million on the line for LaNova Medicines’ preclinical stage ADC.

article source